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Abstract. Neonates with coarctation of the aorta (CoA) 
combined with a bicuspid aortic valve (BAV) show significant 
structural differences compared to neonatal CoA patients 
with a normal tricuspid aortic valve (TAV). These effects are 
likely to change over time in response to growth. This study 
investigated proteomic differences between coarcted aortic 
tissue of BAV and TAV patients in children older than one 
month. Aortic tissue just proximal to the coarctation site was 
collected from 10 children (BAV; n=6, 1.9±1.7 years, TAV; 
n=4, 1.7±1.5 years, (mean ± SEM, P=0.92.) Tissue were snap 
frozen, proteins extracted, and the extracts used for proteomic 
and phosphoproteomic analysis using Tandem Mass Tag 
(TMT) analysis. A total of 1811 protein and 76 phosphoprotein 
accession numbers were detected, of which 40 proteins and 
6 phosphoproteins were significantly differentially expressed 
between BAV and TAV patients. Several canonical pathways 
involved in inflammation demonstrated enriched protein 
expression, including acute phase response signalling, EIF2 
signalling and macrophage production of IL12 and reac‑
tive oxygen species. Acute phase response signalling also 
demonstrated enriched phosphoprotein expression, as did 
Th17 activation. Other pathways with significantly enriched 
protein expression include degradation of superoxide radi‑
cals and several pathways involved in apoptosis. This work 
suggests that BAV CoA patients older than one month have 
an altered proteome consistent with changes in inflammation, 
apoptosis and oxidative stress compared to TAV CoA patients 
of the same age. There is no evidence of structural differences, 
suggesting the pathology associated with BAV evolves with 
age in paediatric CoA patients.
Introduction
One of the most common congenital cardiac abnormalities 
is coarctation of the aorta (CoA) (1). Around 85% of CoA 
patients also have a bicuspid aortic valve (BAV) (2). Following 
CoA repair, patients are at increased risk of developing cardio‑
vascular complications including hypertension, impaired 
left ventricular function, aortic aneurysms and aortic dissec‑
tion (3‑5). Several studies have demonstrated that the risks are 
greater in CoA patients with BAV compared to CoA patients 
with the normal tricuspid valve (TAV) (6‑8). The co‑existence 
of BAV and CoA is known to alter aortic blood flow haemody‑
namics, and this may underlie the increased susceptibility of 
CoA patients with BAV to cardiovascular complications (9,10).
A recent study by our group was the first to investigate 
differences in the vascular proteome of CoA patients with and 
without BAV (11). This study focused on neonatal patients 
(less than 3 weeks old) and demonstrated that the presence 
of BAV in neonatal CoA patients is associated with altered 
expression of proteins involved in elastin fibre formation and 
oxidative stress. In older CoA patients, there will have been 
more time for aortic remodelling to occur in response to 
the altered blood flow haemodynamics, and this will likely 
effect protein expression. Therefore, molecular changes in the 
coarctation area will be influenced not just by the valve and 
blood flow haemodynamics, but also the effects of growth. 
The current study therefore compares the proteome of CoA 
patients with and without BAV in paediatric patients older 
than one month, thus providing a unique insight into how the 
proteomic changes associated with BAV evolve in an older 
group of CoA patients.
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Materials and methods
Patients and sample collection. Tissue was collected from 
paediatric patients older than one month undergoing congen‑
ital surgery including repair of an aortic coarctation. Tissue 
was collected just proximal to the coarctation site. The study 
was conducted in accordance with the declaration of Helsinki, 
and the protocol was approved by the North Somerset and 
South Bristol Research Ethics Committee (Health Research 
Authority, Whitefriars, Level 3 Block B, Lewins Mead, Bristol, 
BS1 2NT, REC 07/H0106/172). Full informed consent was 
obtained from parents prior to admission for operation. The 
tissue was snap frozen in liquid nitrogen before being stored 
at ‑80˚C (BAV: n=6, patient age 1.9±1.7 years (mean ± SEM). 
TAV: n=4, patient age 1.7±1.5 years).
Sample preparation. Proteins were extracted in radio‑ 
immuno‑precipitation assay buffer (RIPA; 1% Nonidet P‑40, 
0.5% sodium deoxycholate, 0.1% SDS, in PBS with phospha‑
tase and protease inhibitors), and quantified using Bradford's 
assay. Aliquots of 100 µg were digested (2.5 µg trypsin, 37˚C, 
overnight), labelled with Tandem Mass Tag (TMT) 10Plex 
reagents (Thermo Fisher Scientific, Loughborough, UK) and 
the labelled samples pooled. For total proteome analysis, 
aliquots of 50 µg of the pooled sample were dried, re‑suspended 
in buffer A (20 mM ammonium hydroxide, pH 10) and frac‑
tionated by high pH reversed‑phase (RP) chromatography 
(UltiMate 3000 liquid chromatography system (Thermo 
Fisher Scientific) with XBridge BEH C18 Column (130 Å, 
3.5 µm, 2.1x150 mm, Waters, UK). The samples were loaded 
in buffer A and peptides eluted with an increasing gradient of 
buffer B (20 mM ammonium hydroxide in acetonitrile, pH 10, 
0‑95% over 60 min). The resulting fractions were dried and 
re‑suspended in 1% (v/v) formic acid. The remainder of the 
TMT‑labelled pooled sample was dried and enriched using 
a TiO2 based phosphopeptide enrichment protocol (Pierce), 
before further drying and re‑suspension in 1% (v/v) formic 
acid.
Nano‑LC mass spectrometry. Mass spectrometry was 
performed using an Ultimate 3000 nano‑HPLC system 
in line with an Orbitrap Fusion Tribrid mass spectrometer 
(Thermo Scientific). The samples were injected onto an 
Acclaim PepMap C18 nano‑trap column (Thermo Scientific), 
washed (0.5% v/v acetonitrile, 0.1% v/v formic acid) and 
resolved on a 250 mm x 75 µm Acclaim PepMap C18 reverse 
phase analytical column (Thermo Scientific) over an organic 
gradient (150 min, flow rate 300 nl/min, solvent A: 0.1% 
formic acid, solvent B: Aqueous 80% acetonitrile in 0.1% 
formic acid, seven gradient segments: 1‑6% B over 1 min, 
6‑15% B over 58 min, 15‑32% B over 58 min, 32‑40% B 
over 5 min, 40‑90% B over 1 min, held at 90% B for 6 min 
and then reduced to 1% B over 1 min). Nano‑electrospray 
ionization was used to ionize the peptides (2.0 kV, stainless 
steel emitter internal diameter 30 µm (Thermo Scientific), 
capillary temperature 275˚C).
Spectra were acquired using an Orbitrap Fusion Tribrid mass 
spectrometer with Xcalibur 3.0 software (Thermo Scientific), 
operated using an SPS‑MS3 workflow and data‑dependent 
acquisition mode. For FTMS1 spectra a resolution of 120,000 
was used, alongside an automatic gain control (AGC) target of 
200,000 and a maximum injection time of 50 ms. Precursors 
were filtered with an intensity threshold of 5000, with 
monoisotopic peak determination set to peptide and to include 
charge states 2‑7. Previously interrogated precursors were 
excluded with a dynamic window (60s +/‑10 ppm). The MS2 
precursors were isolated with a quadrupole mass filter (width 
of 1.2 m/z). ITMS2 spectra were collected (AGC target 10000, 
max injection time 70ms, CID collision energy 35%). FTMS3 
analysis was then performed (resolution 50,000, AGC target 
50,000, max injection time 105 ms). Fragmentation of precur‑
sors was achieved using high‑energy collision dissociation at 
normalised collision energy of 60%. Synchronous Precursor 
Selection (SPS) was enabled to include up to five MS2 frag‑
ment ions in the FTMS3 scan.
Data processing and analysis. Processing and quantifica‑
tion of the raw data files was performed using Proteome 
Discoverer Software (Thermo Scientific, version 1.4). Peptide 
sequences were searched against the Uniprot human data‑
base (SEQUEST algorithm, peptide precursor mass tolerance 
10 ppm, MS/MS tolerance 0.6Da). Oxidation of methionine 
(+15.9949) was included as a variable modification, and both 
carbamido‑methylation of cysteine (+57.0214) and the addition 
of the TMT mass tag (+229.163) to peptide N‑termini and 
lysine were included as fixed modifications. Phosphorylation 
of serine, threonine and tyrosine (+79.966) were also included 
as variable modifications in the phosphoproteomic analysis. 
Searches were performed with full tryptic digestion, allowing 
a maximum of one missed cleavage. The reverse database 
search option was enabled, and all the data filtered to satisfy 
false discovery rate of 5%.
Proteins or phosphoproteins with more than one missing 
value per group were excluded from the analysis (12), as were 
putative uncharacterized proteins and proteins with accession 
numbers representing cDNA with weak similarity. Values 
are presented as a ratio to the internal standard (a pool of all 
samples) and represent the median of the measured peptide(s) 
for each protein. Fold change (BAV/TAV) ratios were 
calculated, and log2 (fold‑change) was plotted against ‑log10 
(P‑value) on a volcano plot. A change in protein expression 
greater than 1.3x or less than ‑1.3x and with P<0.05 (Student's 
t‑test) was considered significant. These cut offs were chosen 
in accordance with other similar studies, for example (13). A 
heatmap was plotted using R software (version 3.5.1). QuickGo 
software was used to analyse gene ontology (GO) enrichment. 
Differentially expressed proteins and phosphoproteins were 
inputted into Ingenuity Pathway Analysis software (IPA 
version 46901286, Qiagen, Aarhus, Denmark) to determine 
significantly enriched canonical pathways (P‑value of overlap 
calculated by Fisher's exact test right tailed).
Results
The age range of patients in the study was from one month 
to 10.5 years. The average age was not different significantly 
between groups (TAV; 1.7±1.5 years, BAV; 1.9±1.7 years, 
P=0.92).
A total of 1811 protein accession numbers were detected, 
of which 40 were significantly differentially expressed 
EXPERIMENTAL AND THERAPEUTIC MEDICINE  20:  48,  2020 3
between BAV and TAV patients (Fig. 1A and C, Table I); 
38 proteins upregulated and two proteins downregulated in 
BAV patients compared to TAV patients. A total of 76 phos‑
phorylated proteins were identified, some with multiple 
phosphorylation sites, resulting in 92 phosphorylation site 
matches. 6 phosphoproteins demonstrated significantly 
altered expression in BAV patients compared to TAV 
patients; all 6 demonstrated increased phosphorylation in 
BAV patients (Fig. 1B, Table II).
Gene Ontology (GO) analysis was used to functionally 
classify the GO annotations associated with the differentially 
expressed proteins under the three main categories of GO 
analysis (molecular function, biological process and cellular 
component; Fig. 2). Numerous molecular functions relating to 
protein and ion binding were present in the top ten molecular 
functions, however endopeptidase and superoxide dismutase 
activities were also featured.
The top 20 significantly enhanced canonical pathways for 
protein expression are shown in Table III. The most significantly 
enhanced pathway was the acute phase response, a systemic 
response to inflammation. IPA analysis predicted activation of 
the acute phase response in BAV patients (z‑score=2). Several 
other of the top 20 canonical pathways also relate to inflam‑
mation, including EIF2 signalling and macrophage production 
of IL12 and reactive oxygen species (ROS). Superoxide radical 
degradation was also highlighted as a significantly enriched 
canonical pathway. Finally, a number of canonical pathways 
involved in apoptosis, including Myc mediated apoptosis 
signalling, ceramide signalling and lymphotoxin β receptor 
signalling, were all significantly enriched. Sixteen canonical 
pathways were found to be significantly enriched from the 
phosphoproteomic data (Table IV), including two pathways 
relating to inflammation, namely the acute phase response and 
Th17 activation.
Discussion
Our previous study (11) demonstrated that aortic tissue from 
neonatal CoA patients with BAV have proteomic and histo‑
logical differences compared to TAV CoA patients of the 
same age. The changes included increased elastin content 
and altered expression of genes involved in elastin formation, 
inositol signalling and oxidative stress. The current study 
demonstrates that in older children (>one month) with CoA, 
there are still significant differences between the proteomes 
of BAV and TAV patients, but different proteins and pathways 
are involved, suggesting that the pathology associated with 
CoA not only develops with age, but also develops differently 
in BAV patients compared to TAV patients. Each group of 
patients contains one patient older than one year, whilst the 
others are aged between 1 month and one year. Interestingly, 
the protein expression profile of the two oldest patients are 
not the most extreme in either group (see Fig. 1C); this may 
suggest that the alterations in protein expression are similar in 
children between one month and ten years of age.
The presence of BAV affects the expression of proteins involved 
in inflammatory pathways. The most significantly enriched 
proteomic canonical pathway was acute phase response signal‑
ling, which was predicted to be activated in BAV patients. This 
Figure 1. Differential protein expression. Volcano plots of proteins (A) and phosphoproteins (B) quantified in paediatric patients with bicuspid (BAV) vs. 
tricuspid (TAV) aortic valves. Each point represents the log2 (fold‑change) between the two groups, plotted against the associated significance for the change. 
Proteins in the shaded area (>1.3 or <0.769 fold‑change, P<0.05) are considered to be differentially expressed. (C) A heatmap of the 40 differentially expressed 
proteins. Horizontal dendrogram represents 10 independent samples. Vertical dendrogram represents the 40 proteins analysed, protein identities are listed on 
the right. The numbers at the bottom of each column represent the age of each patient, in years.




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































SKEFFINGTON et al:  MOLECULAR CHANGES IN COARCTED AORTA WITH BAV6
pathway was also significantly enriched in the phosphopro‑
teomics data. The acute phase response is a systemic response 
triggered by major local inflammation and cytokine release. 
Several other inflammatory canonical pathways were also 
significantly enriched. Within the proteomic data, produc‑
tion of NO, ROS and the pro‑inflammatory cytokine IL‑12 
by macrophages were enriched, as was EIF2 signalling [a 
pathway involved in the regulation of pro‑inflammatory 
cytokine expression (14)]. In the phosphoproteome analysis, 
the third most significant canonical pathway was activation of 
Th17 cells, a subset of pro‑inflammatory T helper cells (15).
These changes in canonical pathways related to inflamma‑
tion are driven by significant upregulation of the abundance of 
several proteins and phosphoproteins involved in inflammation 
in BAV patients compared to TAV patients. α‑1‑antitrypsin 
(AAT), α‑1‑antichymotrypsin (ACT) and α‑1‑acid glycoprotein 
2 (AGP) were all overexpressed in BAV patients compared 
to TAV patients. These proteins are all known to regulate 
macrophage function (16‑18) and are all positive acute phase 
proteins (19,20) (proteins whose expression increases during 
an inflammatory episode), as is hemopexin (21), another 
protein overexpressed in BAV patients. AAT and ACT both 
belong to the serpin family of protease inhibitors and provide 
negative feedback of the acute phase response via their inhi‑
bition of inflammatory cells including neutrophils and mast 
cells (22,23). Another member of the serpin family with marked 
anti‑inflammatory properties is anti‑thrombin III (24), and this 
was also overexpressed in BAV patients. BAV patients also 
had overexpression of phosphorylated α‑2 Heremans‑Schmid 
glycoprotein [AHSG; a negative acute phase protein (25,26)] 
and phosphorylated HSP90AB1 [a member of the heat shock 
protein 90 family, which have been demonstrated to increase 
secretion of pro‑inflammatory cytokines (27)].
Several studies have previously suggested that differences in 
basal inflammation may exist between BAV and TAV patients. 
Local inflammation is known to occur around the abnormal 
BAV valve (28), however whether the presence of BAV has 
an effect on aortic or systemic inflammation is less clear. The 
combination of CoA and BAV has been demonstrated to cause 
changes in aortic blood flow haemodynamics including altered 
indices of shear stress (9), factors which are, in turn, known to 
affect vascular inflammatory pathways (29). However, studies 
comparing inflammatory markers such as MMPs, myeloper‑
oxidase or measures of macrophage infiltration in BAV vs. 
TAV patients have mixed conclusions: Some studies found an 
increase in inflammatory markers associated with BAV whilst 
others found no difference or reduced inflammation (30‑34).
The trauma of cardiac surgery is known to activate the 
complement system even when no cardiopulmonary bypass is 
involved (35). Although the full immunological response takes 
hours to days to materialise, markers of complement activation 
and some markers of inflammation start increasing measurably 
during surgery itself (35), and therefore some inflammatory 
proteomic changes are likely to already be occurring at the 
timepoint our samples were taken. It is possible that the 
differences between BAV and TAV patients in the current 
study indicate that BAV patients have a greater inflammatory 
response to surgery than TAV patients. Possibly changes in 
both basal immunological status and in the response to surgery 
exist. One recent paper found that BAV patients have decreased 
T and B lymphocyte levels and the authors suggested that BAV 
patients have ‘an old immune system’ which is ‘more easily 
vulnerable to internal and external stressors’ (31).
The presence of BAV affects the expression of proteins 
involved in oxidative stress and apoptosis. The antioxidant 
Figure 2. Functional classification by Gene Ontology (GO) analysis of proteins differentially expressed between BAV and TAV paediatric patients. The top 10 
GO terms in each of the three main categories of GO classification (molecular function, cellular component and biological process) are displayed. The y axis 
represents the percentage of annotations per GO term.
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enzyme cytosolic superoxide dismutase (SOD1) was signifi‑
cantly overexpressed in BAV CoA patients compared to 
CoA patients with a normal aortic valve, and superoxide 
radical degradation and superoxide dismutase activity were 
highlighted in canonical pathway analysis and gene ontology 
analysis respectively (Fig. 2 and Table III). These findings 
suggest there may be differences in the levels of oxidative 
stress between BAV and TAV CoA patients. Previous studies 
have demonstrated that adult BAV patients have increased 
aortic oxidative stress compared to similar patients with a 
morphologically normal aortic valve (36). This may be the 
result of altered mechanical stretch in the aortic walls of BAV 
patients as vascular mechanical stretch is a known stimulant of 
superoxide production (37). A previous study in adults found 
Table III. Top twenty significant canonical pathways with enriched protein expression. IPA: Ingenuity Pathway Analysis.
IPA canonical pathway P‑value Molecule(s)
Acute Phase Response Signalling 1.52x10‑5 HPX, AKT3, ORM2, SERPINA1, SERPINA3
FXR/RXR Activation 7.10x10‑5 HPX, AKT3, ORM2, SERPINA1
Amyotrophic Lateral Sclerosis Signalling 1.04x10‑3 AKT3, CYCS, SOD1
LXR/RXR Activation 1.27x10‑3  HPX, ORM2, SERPINA1
Coagulation System 1.74x10‑3  SERPINC1, SERPINA1
Iron homeostasis signalling pathway 1.81x10‑3 HPX, HBD, HBB
tRNA Charging 2.16x10‑3 NARS, WARS
IL‑12 Signalling and Production in Macrophages 2.26x10‑3 ORM2, AKT3, SERPINA1
Formaldehyde Oxidation II (Glutathione‑dependent) 3.53x10‑3  ADH5
Docosahexaenoic Acid (DHA) Signalling 4.10x10‑3 AKT3, CYCS
Production of Nitric Oxide and Reactive Oxygen 5.55x10‑3 ORM2, AKT3, SERPINA1
Species in Macrophages
Lymphotoxin β Receptor Signalling 6.61x10‑3 AKT3, CYCS
Phenylalanine Degradation I (Aerobic) 7.04x10‑3  QDPR
EIF2 Signalling 7.90x10‑3  WARS, AKT3, EIF1AY
Myc Mediated Apoptosis Signalling 8.79x10‑3 AKT3, CYCS
Small Cell Lung Cancer Signalling 1.03x10‑2 AKT3, CYCS
Superoxide Radicals Degradation 1.40x10‑2  SOD1
Ceramide Signalling 1.45x10‑2 AKT3, CYCS
VEGF Signalling 1.73x10‑2 AKT3, EIF1AY
Glucose and Glucose‑1‑phosphate Degradation 1.92x10‑2 RGN
Table IV. Significant canonical pathways with enriched phosphoprotein expression. IPA: Ingenuity Pathway Analysis.
IPA canonical pathway P‑value Molecule
Mitotic Roles of Polo‑Like Kinase 1.77x10‑2 HSP90AB1
Hypoxia Signalling in the Cardiovascular System 1.99x10‑2 HSP90AB1
Th17 Activation Pathway 2.44x10‑2 HSP90AB1
Prostate Cancer Signalling 2.47x10‑2 HSP90AB1
Neuregulin Signalling 2.57x10‑2 HSP90AB1
Nitric Oxide Signalling in the Cardiovascular System 2.68x10‑2 HSP90AB1
PPAR Signalling 2.78x10‑2 HSP90AB1
Telomerase Signalling 2.89x10‑2 HSP90AB1
LXR/RXR Activation 3.23x10‑2 AHSG
FXR/RXR Activation 3.36x10‑2 AHSG
PI3K/AKT Signalling 3.52x10‑2 HSP90AB1
Iron homeostasis signalling pathway 3.65x10‑2 CYBRD1
Aryl Hydrocarbon Receptor Signalling 3.81x10‑2 HSP90AB1
Aldosterone Signalling in Epithelial Cells 4.23x10‑2 HSP90AB1
eNOS Signalling 4.26x10‑2 HSP90AB1
Acute Phase Response Signalling 4.75x10‑2 AHSG
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increased SOD1 expression in the aorta of some subsets of 
BAV patients (38); to the best of our knowledge the data in 
the current study is the first to suggest that an association of 
increased SOD1 expression with BAV also exists in paediatric 
CoA patients. However it is interesting that in our neonatal 
data set (11) there is no significant difference in SOD1 expres‑
sion, suggesting the change in expression may only occur in 
older children.
Previous studies in neonates with BAV associated with 
CoA and adults with BAV have demonstrated decreased 
expression of the extracellular form of superoxide dismutase 
(SOD3) associated with BAV (11,38,39), however there was 
no significant change in SOD3 expression in the current data 
set. One of only two proteins to be significantly downregu‑
lated in BAV patients was however carbonic anhydrase III, 
which is known to have an antioxidant role under conditions 
of oxidative stress (40). Clearly much more work is required 
to understand the changes in oxidative stress and antioxidant 
defence mechanisms which occur at different ages in BAV 
patients with and without CoA.
Two proteins involved in apoptotic pathways, AKT3 and 
cytochrome c, were also significantly overexpressed in BAV 
CoA patients compared to TAV CoA patients. This resulted in 
the enrichment of a number of canonical pathways (Myc medi‑
ated apoptosis signalling, ceramide signalling and lymphotoxin 
β receptor signalling) which are involved in apoptosis (41‑43). 
Several previous studies have reported an increase in vascular 
smooth muscle cell (VSMC) apoptosis in BAV patients, and 
have linked this to the increased incidence of in aortic dilation 
and aortic aneurysms in BAV patients (44‑47). The degree 
to which this is a genetic effect or secondary to changes in 
blood flow haemodynamics, or a combination of both factors, 
is controversial (44,48‑50).
Interestingly, there were also alterations in the ratio of 
haemoglobin chains. Various haemoglobin subunits are 
expressed in a number of non‑erythroid cells, including lungs, 
neurons, endometrium and blood vessel walls (51,52). In 
the current study there was overexpression of haemoglobins 
beta and delta in the aorta of BAV CoA patients compared 
to TAV CoA patients. The role of the beta and delta subunits 
in the aortic wall is unclear however it has been suggested 
that haemoglobin α acts from within blood vessel walls to 
help regulate nitric oxide release and vascular tone (51). It 
is possible therefore that the observed changes relate to the 
altered blood flow haemodynamics in BAV patients, however 
much more work is needed to understand this.
Paediatric CoA patients with BAV have a greater long‑term 
risk of cardiovascular complications than similar patients with 
TAV (6‑8). This study demonstrates significant differences 
between the proteome of the coarcted aortic tissue of young 
CoA patients with and without BAV, indicating that inflamma‑
tion, oxidative stress and apoptotic pathways could contribute 
to future complications associated with BAV patients. The 
structural changes observed in our previous study in neonates 
are no longer apparent. In the long‑term, improved under‑
standing of the molecular differences between these patients 
coupled with an understanding of how the changes evolve with 
age should help to optimise treatment strategies.
Limitations of the study include the lack of tissue from a 
healthy control group; this would help to elucidate how the 
proteomic differences observed in BAV patients in this study 
are affected by the presence of the CoA. However, such tissues 
would be very difficult to obtain. Using tissues from only 
diseased individuals may also increase the likelihood that 
pathways are involved which deviate from the canonical para‑
digms, and these may not have been fully uncovered by our 
analysis. Slight regional differences in the exact location of the 
tissue collection may also have introduced some variation into 
our analyses. Additionally, validation of the changes in protein 
expression using western blotting would be informative, 
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